Last reviewed · How we verify
Cyclosporine Pill
Cyclosporine inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.
Cyclosporine inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription. Used for Organ transplant rejection prophylaxis, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, nephrotic syndrome).
At a glance
| Generic name | Cyclosporine Pill |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (serine/threonine phosphatase) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine binds to cyclophilin and the resulting complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). This prevents NFAT translocation to the nucleus and subsequent IL-2 and other cytokine gene expression, thereby suppressing T-cell mediated immune responses. It is a non-selective immunosuppressant used primarily in transplantation and autoimmune conditions.
Approved indications
- Organ transplant rejection prophylaxis
- Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, nephrotic syndrome)
Common side effects
- Nephrotoxicity
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Infection
- Hyperkalemia
Key clinical trials
- A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection (PHASE2)
- Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study (NA)
- Comparison of Safety and Efficacy of de Novo Everolimus (NA)
- Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis (PHASE3)
- Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action (PHASE2)
- A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity (PHASE4)
- Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients (PHASE1)
- Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine Pill CI brief — competitive landscape report
- Cyclosporine Pill updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI